---
title: "Sinopharm Accord Q1 2026 Preliminary Results Show Profit Decline Amid Stable Asset Base"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/283493274.md"
description: "Sinopharm Group Co. has released preliminary Q1 2026 results for its subsidiary Sinopharm Accord, indicating a decline in profitability despite stable asset growth. Revenue decreased by 2.57% to RMB 178.23 billion, with operating profit down 14.24% and net profit attributable to shareholders falling 12.36%. Earnings per share dropped to RMB 0.52, while total assets rose slightly by 0.06%. The stock is currently rated as a Buy with a price target of HK$22.50."
datetime: "2026-04-21T11:46:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/283493274.md)
  - [en](https://longbridge.com/en/news/283493274.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/283493274.md)
---

# Sinopharm Accord Q1 2026 Preliminary Results Show Profit Decline Amid Stable Asset Base

### Claim 30% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Sinopharm Group Co ( (HK:1099) ) just unveiled an update.

Sinopharm Group has released preliminary unaudited first-quarter 2026 figures for its Shenzhen-listed subsidiary Sinopharm Accord, showing a slight contraction in top-line performance alongside softer profitability metrics. The update offers investors an early view of the unit’s operating momentum and capital position, highlighting modest asset growth despite earnings pressure.

For the three months to 31 March 2026, Sinopharm Accord’s revenue slipped 2.57% year on year to RMB 178.23 billion, while operating profit fell 14.24% and net profit attributable to shareholders declined 12.36%. Earnings per share eased to RMB 0.52 and weighted average return on equity narrowed by 0.31 percentage point, although total assets edged up 0.06% and equity attributable to shareholders increased 1.54%, supporting a small rise in net asset value per share.

The most recent analyst rating on (HK:1099) stock is a Buy with a HK$22.50 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.

**More about Sinopharm Group Co**

Sinopharm Group Co. Ltd. is a major Chinese pharmaceutical conglomerate with subsidiaries engaged in the distribution and retail of medicines and related healthcare products. Its subsidiary China National Accord Medicines Corporation Ltd. (Sinopharm Accord) is listed in Shenzhen with both A and B shares, focusing on pharmaceutical commerce and related services across mainland China.

**Average Trading Volume:** 5,740,011

**Technical Sentiment Signal:** Strong Buy

**Current Market Cap:** HK$65.03B

For a thorough assessment of 1099 stock, go to TipRanks’ Stock Analysis page.

### Related Stocks

- [01099.HK](https://longbridge.com/en/quote/01099.HK.md)
- [000028.CN](https://longbridge.com/en/quote/000028.CN.md)
- [200028.CN](https://longbridge.com/en/quote/200028.CN.md)

## Related News & Research

- [Sinopharm Group Co (SHTDF) Gets a Buy from CLSA](https://longbridge.com/en/news/284466436.md)
- [Sinopharm posts unaudited Q1 2026 figures, highlighting RMB 400.8bn asset base](https://longbridge.com/en/news/284128644.md)
- [China XLX Announces 2026 Q1 Results | CXLFF Stock News](https://longbridge.com/en/news/286673637.md)
- [11:48 ETInventHelp Inventor Develops New Remote Control Finder (TKA-458)](https://longbridge.com/en/news/286941635.md)
- [16:51 ETBeverly Hills MD ProRetinol Age Rewind x3 Officially Launches: A New Era of Gentle, Slow-Released Retinol Skincare Backed by Plastic Surgeons](https://longbridge.com/en/news/286966075.md)